Bruker Corporation (NASDAQ:BRKR) Receives Average Rating of “Hold” from Analysts

Bruker Corporation (NASDAQ:BRKR) has received a consensus rating of “Hold” from the fifteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $50.5385.

Several research firms have recently commented on BRKR. Citigroup raised their target price on shares of Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. UBS Group raised their target price on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a research note on Thursday, February 12th. Finally, Weiss Ratings cut shares of Bruker from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sector Gamma AS lifted its stake in shares of Bruker by 28.0% in the third quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock valued at $8,152,000 after purchasing an additional 54,939 shares during the period. Becker Capital Management Inc. lifted its stake in shares of Bruker by 606.8% in the third quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after purchasing an additional 258,545 shares during the period. DNB Asset Management AS lifted its stake in shares of Bruker by 40.5% in the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after purchasing an additional 41,289 shares during the period. Aquatic Capital Management LLC lifted its stake in shares of Bruker by 120.3% in the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock valued at $11,358,000 after purchasing an additional 190,883 shares during the period. Finally, M&G PLC lifted its stake in shares of Bruker by 233.0% in the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock valued at $35,079,000 after purchasing an additional 766,992 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Trading Down 2.9%

Shares of Bruker stock opened at $42.88 on Tuesday. Bruker has a 1 year low of $28.53 and a 1 year high of $56.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The company has a market capitalization of $6.53 billion, a P/E ratio of -178.67, a PEG ratio of 2.57 and a beta of 1.12. The company’s fifty day moving average is $37.75 and its two-hundred day moving average is $42.25.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter last year, the business earned $0.47 EPS. The business’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts forecast that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.